MME Kim Loan NGUYEN

Rhumatologue

📍 PARIS (75)SalariéRPPS 10001601516

✨ Profil synthétique

IA · 23/05/2026

MME Kim Loan NGUYEN est une rhumatologue exerçant à Paris. Ses publications sur PubMed couvrent divers domaines, notamment la pédiatrie, les essais cliniques et l'épidémiologie. Elle a également publié des travaux sur l'économie de la santé et la génétique.

Expertises présumées

Rhumatologie pédiatrique
Essais cliniques
Épidémiologie des maladies rhumatismales
Génétique des maladies auto-immunes
Économie de la santé dans les maladies rhumatismales
Registres de maladies rhumatismales
Recherche en santé

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(2)

QARE SANTE
10 R DE PENTHIEVRE, 75008 PARIS
Activité de soin et de pharmacie
COMMUNE DE CHAMPIGNY SUR MARNE
MAIRIE 14 RUE LOUIS TALAMONI 94507, 94500 CHAMPIGNY SUR MARNE
Activité non soignante

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Progression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation

Science translational medicine · 2025

📚 10 citations🎯 RCR 3.51🔓 Open Access

Lire l'abstract Crossref ↓

Rheumatoid arthritis (RA) is preceded by an at-risk stage of disease that can be marked by the presence of anticitrullinated protein antibodies (ACPAs) but the absence of clinically apparent synovitis (clinical RA). Preemptive intervention in at-risk individuals could prevent or delay future tissue damage; however, the immunobiology of this stage is unclear. Using integrative multiomics, we longitudinally profiled at-risk individuals, where one-third of participants developed clinical RA on study. We found evidence of systemic inflammation and signatures of activation in naïve T and B cells of at-risk individuals. During progression to clinical RA, proinflammatory skewing of atypical B cells and expansion of memory CD4 T cells with signatures of activation and B cell help were present without elevations in circulating ACPA titers. Epigenetic changes in naïve CD4 T cells suggested a predisposition to differentiate into effector cells capable of B cell help. These findings characterize pathogenesis of the ACPA + at-risk stage and support the concept that the disease begins much earlier than clinical RA. Additionally, an extensive immune resource of the at-risk stage and progression to clinical RA with interactive tools was developed to enable further investigation.

Transparent Reporting of Pediatric Clinical Trial Interventions: TIDieR-Children and Adolescents

Pediatrics · 2025

📚 6 citations🎯 RCR 2.81

Lire l'abstract Crossref ↓

Pediatric randomized controlled trials (RCTs) inform decisions concerning the choice of interventions in children and adolescents. To enable the implementation of effective interventions, RCT reports need to provide adequate details on the elements, infrastructure, and delivery of these interventions. Using the 12-item Template for the Intervention Description and Replication (TIDieR) framework, an international team developed guidance for comprehensive reporting of trial interventions in pediatric RCT protocols and reports. We (1) identified initial pediatric considerations (PCs) and examples of good reporting using 50 recent pediatric RCT reports, (2) held an expert panel meeting, (3) conducted a Family Caregiver Workshop to discuss and get input on PCs, (4) compiled PCs and examples of good reporting, and (5) achieved consensus on final PCs and examples. Thirteen PCs reached consensus; they address how trial intervention materials were appropriate for the age and developmental stage of trial participants, which adjustments to enhance palatability of medications and acceptability of interventions were implemented, and how pediatric-specific dosing was determined. Consensus was also reached on accompanying good reporting exemplars. Presenting a minimum set of considerations pertinent to pediatric trial interventions, the TIDieR-Child & Adolescent Health (TIDieR-C) checklist can help trial authors and evidence end users comprehensively report and appraise tested interventions. It can be used with the pediatric-specific extensions of the Standard Protocol Items for Randomized Trials (SPIRIT) and Consolidated Standards of Reporting Trials (CONSORT): SPIRIT-Children & Adolescents and CONSORT-Children & Adolescents. Uptake of this guidance may lead to improved understanding, replicability, and implementation fidelity of effective trial interventions.

SPIRIT-Children and Adolescents (SPIRIT-C) 2026 extension statement: enhancing the reporting and usefulness of paediatric randomised trial protocols

BMJ (Clinical research ed.) · 2026

📚 5 citations🎯 RCR 5.00🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

MME Kim Loan NGUYEN

Pourquoi vous devez consulter ce praticien

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (33) — classées par pathologie

Pédiatrie13

Essai clinique8

Transversal4

Case report / série3

Épidémiologie & registres3

Économie santé2

Génétique2

Biothérapies non-anti-TNF1

Gériatrie1

Goutte1

Pharmacovigilance1

Qualité de vie / PROMs1

Revue / méta-analyse1

Revue générale1

Spondyloarthrite1

Vraie vie / RWE1

Partager cette fiche